Amy R Dwyer1, Thu H Truong1, Carlos Perez Kerkvliet1, Kiran V Paul2, Peter Kabos2, Carol A Sartorius3, Carol A Lange4,5. 1. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. 2. Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. 3. Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA. 4. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, 55455, USA. lange047@umn.edu. 5. Departments of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology, University of Minnesota, Minneapolis, MN, 55455, USA. lange047@umn.edu.
Abstract
BACKGROUND: Progesterone receptors (PR) are potent modifiers of endocrine responses. In aberrant signalling cancer contexts, phosphorylation events dramatically alter steroid hormone receptor action. METHODS: The transcriptomes of primary tumours and metastases in mice harbouring ER+ breast cancer patient-derived xenografts (PDXs) were analysed following single-cell RNAseq. In vitro assays were employed to delineate mechanisms of endocrine resistance and stemness. RESULTS: A 16-gene phospho-Ser294 PR (p-PR) signature predicted poor outcome in ER+ breast cancer. Relative to primary PDX tumours, metastatic lesions expressed abundant p-PR and exhibited an activated PR gene programme with elevated expression of PGR and IRS-1. Breast cancer models of activated PR lost the expression of IGF1R and acquired insulin hypersensitivity with tamoxifen insensitivity. Activated p-PR+ breast cancer cells formed increased tumourspheres with enlarged ALDH+ and CD24-/CD44 populations. E2 induced PR/IRS-1 interaction and exchange of IGF1Rβ for IRS-1 in p-PR-containing transcriptional complexes. Inhibition of IRS-1 or IR and inducible IRS-1 knockdown reduced tumourspheres. Endocrine-resistant models of luminal B breast cancer induced p-PR in 3D cultures and required PR and IRS-1 for tumoursphere formation. CONCLUSIONS: Phospho-PR-B cooperates with IRS-1 to promote outgrowth of endocrine-resistant and stem-like breast cancer cells. Targeting phospho-PR/IRS-1 crosstalk may block the emergence of endocrine resistance.
BACKGROUND: Progesterone receptors (PR) are potent modifiers of endocrine responses. In aberrant signalling cancer contexts, phosphorylation events dramatically alter steroid hormone receptor action. METHODS: The transcriptomes of primary tumours and metastases in mice harbouring ER+ breast cancerpatient-derived xenografts (PDXs) were analysed following single-cell RNAseq. In vitro assays were employed to delineate mechanisms of endocrine resistance and stemness. RESULTS: A 16-gene phospho-Ser294 PR (p-PR) signature predicted poor outcome in ER+ breast cancer. Relative to primary PDX tumours, metastatic lesions expressed abundant p-PR and exhibited an activated PR gene programme with elevated expression of PGR and IRS-1. Breast cancer models of activated PR lost the expression of IGF1R and acquired insulin hypersensitivity with tamoxifen insensitivity. Activated p-PR+ breast cancer cells formed increased tumourspheres with enlarged ALDH+ and CD24-/CD44 populations. E2 induced PR/IRS-1 interaction and exchange of IGF1Rβ for IRS-1 in p-PR-containing transcriptional complexes. Inhibition of IRS-1 or IR and inducible IRS-1 knockdown reduced tumourspheres. Endocrine-resistant models of luminal B breast cancer induced p-PR in 3D cultures and required PR and IRS-1 for tumoursphere formation. CONCLUSIONS: Phospho-PR-B cooperates with IRS-1 to promote outgrowth of endocrine-resistant and stem-like breast cancer cells. Targeting phospho-PR/IRS-1 crosstalk may block the emergence of endocrine resistance.
Authors: Naokazu Ibuki; Mazyar Ghaffari; Hadas Reuveni; Mitali Pandey; Ladan Fazli; Haruhito Azuma; Martin E Gleave; Alexander Levitzki; Michael E Cox Journal: Mol Cancer Ther Date: 2014-09-29 Impact factor: 6.261
Authors: P M O'Connor; J Jackman; I Bae; T G Myers; S Fan; M Mutoh; D A Scudiero; A Monks; E A Sausville; J N Weinstein; S Friend; A J Fornace; K W Kohn Journal: Cancer Res Date: 1997-10-01 Impact factor: 12.701
Authors: Thu H Truong; Amy R Dwyer; Caroline H Diep; Hsiangyu Hu; Kyla M Hagen; Carol A Lange Journal: Endocrinology Date: 2019-02-01 Impact factor: 4.736
Authors: Todd P Knutson; Andrea R Daniel; Danhua Fan; Kevin At Silverstein; Kyle R Covington; Suzanne Aw Fuqua; Carol A Lange Journal: Breast Cancer Res Date: 2012-06-14 Impact factor: 6.466
Authors: A R Daniel; A L Gaviglio; T P Knutson; J H Ostrander; A B D'Assoro; P Ravindranathan; Y Peng; G V Raj; D Yee; C A Lange Journal: Oncogene Date: 2014-01-27 Impact factor: 9.867
Authors: Svetlana E Semina; Purab Pal; Nidhi S Kansara; Rosemary J Huggins; Elaine T Alarid; Geoffrey L Greene; Jonna Frasor Journal: Breast Cancer Res Date: 2022-03-09 Impact factor: 6.466
Authors: Carol A Lange; Julie H Ostrander; Thu H Truong; Elizabeth A Benner; Kyla M Hagen; Nuri A Temiz; Carlos Perez Kerkvliet; Ying Wang; Emilio Cortes-Sanchez; Chieh-Hsiang Yang; Marygrace C Trousdell; Thomas Pengo; Katrin P Guillen; Bryan E Welm; Camila O Dos Santos; Sucheta Telang Journal: Oncogene Date: 2021-06-08 Impact factor: 8.756